Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs
Molecules · 2025
DOI: 10.3390/molecules30040760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Robert F Anderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Hauptthemen laut MEDLINE: Prodrugs, Ubiquinone, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Auckland Doctoral Scholarship, the Schools of Medical Sciences and Chemical Science.
Abstract (Originalsprache)
The kinetic parameters for the release of anticancer effectors from the radical anions of prodrugs through fragmentation have been measured under conditions that model the interfacial region where the enzymatic reduction in the prodrugs takes place. While the back-oxidation of the radical anions via O2 mainly occurs under normoxia, preventing radical anion fragmentation, this is not the case for the lower concentrations of O2 found in hypoxic regions of tumors. Rate-constant data show that O2 concentrations known to bring about a 50% decrease in the level of cell kill arising from the prodrugs in anoxia (the K-value) do not significantly inhibit the fragmentation of radical anions. Evidence is put forward suggesting that radical anions can undergo an electron transfer to ubiquinone (CoQ10, UQ) in competition with the fragmentation of the radical anions releasing effectors. The prior inhibition of the synthesis of UQ in cells is put forward as a possible approach to increase the effectiveness of such prodrugs in killing hypoxic tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
ORCID-Profile: Robert F Anderson, Wen Qi
Förderung
- The University of Auckland Doctoral Scholarship
- the Schools of Medical Sciences and Chemical Science
Zitieren
APA
Anderson, R. F., & Qi, W. (2025). Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs. Molecules. https://doi.org/10.3390/molecules30040760
Vancouver
Anderson RF, Qi W. Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs. Molecules. 2025. doi:10.3390/molecules30040760
BibTeX
@article{Anderson2025,
author = {Anderson, Robert F and Qi, Wen},
title = {Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30040760}
}
EUVIMED